布地奈德联合地塞米松雾化吸入治疗急性感染性咽喉炎的临床研究  

Clinical trial of inhalation of budesonide combined with dexamethasone in the treatment of acute infectious pharyngitis

作　　者：符牧[1] 程钢[1] 杨中川[1] 赵迎彬[1] 梁颖[1] FU Mu;CHENG Gang;YANG Zhong-chuan;ZHAO Ying-bin;LIANG Ying(Department of Otorhinolaryngology,Haikou People,s Hospital,Haikou 570208,Hainan Province,China)

机构地区：[1]海口市人民医院耳鼻咽喉科

出　　处：《中国临床药理学杂志》2019年第23期3013-3016,共4页The Chinese Journal of Clinical Pharmacology

基　　金：海南省卫生厅科研基金资助项目(20168315)

摘　　要：目的观察布地奈德联合地塞米松雾化吸入治疗急性感染性咽喉炎的临床疗效。方法将72例急性感染性咽喉炎患儿随机分为对照组和试验组,各36例。对照组给予基础治疗;试验组在对照组的基础上给予地塞米松1 mg·kg^-1+布地奈德1 mg,雾化吸入。2组均持续治疗7 d。治疗前后采集血液样本,测定血清高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、干扰素-γ(IFN-γ)和免疫球蛋白E(IgE)水平,观察临床症状消失时间,同时比较2组患者的临床疗效及药物不良反应发生情况。结果治疗后,对照组和试验组总有效率分别为77.78%,94.44%,差异有统计学意义(P<0.05)。治疗后,对照组和试验组hs-CRP分别为(4.58±1.05),(3.61±1.01)mg·L^-1,IL-6分别为(60.42±10.49),(52.36±9.17)pg·mL^-1,IFN-γ分别为(81.38±8.37),(88.67±8.51)ng·L^-1,IgE分别为(71.28±12.16),(48.28±11.03)μg·L^-1,差异均有统计学意义(均P<0.05)。2组在发热、呼吸困难、声音嘶哑及犬吠样咳嗽消失时间差异均有统计学意义(均P<0.05)。对照组的药物不良反应主要为胃部不适、轻度发热,试验组主要为纳差、呛咳、鼻分泌物增多。对照组和试验组的药物不良反应发生率分别为11.11%和13.89%,差异无统计学意义(P>0.05)。结论布地奈德联合地塞米松雾化吸入有利于缩短临床症状缓解时间,降低炎性介质,提高治疗效果。Objective To investigate the clinical efficacy of inhalation of budesonide combined with dexamethasone in the treatment of acute infectious pharyngitis.Methods A total of 72 cases of children with acute infectious pharyngitis were randomly divided into control group and treatment group,36 cases in each group.Control group was given basic treatment.On the basis of control group,treatment group was given dexamethasone 1 mg·kg^-1+budesonide 1 mg,inhalation.The two groups were treated continuously for 7 d.Blood samples were collected before and after treatment,the levels of serum high-sensitivity C reactive protein(hs-CRP),interleukin-6(IL-6),interferon-γ(IFN-γ)and immunoglobulin IgE were determined,the time of disappearance of clinical symptoms was observed,and the clinical efficacy,adverse drug reactions were compared between two groups.Results After treatment,the total efficiencies in control group and treatment group were 77.78%,94.44%,with significant difference(P<0.05).After treatment,the levels of hs-CRP in control group and treatment group were(4.58±1.05),(3.61±1.01)mg·L^-1,IL-6 were(60.42±10.49),(52.36±9.17)pg·mL^-1,IFN-γwere(81.38±8.37),(88.67±8.51)ng·L^-1,IgE were(71.28±12.16),(48.28±11.03)μg·L^-1,all had statistical significances(all P<0.05).The disappearance time of fever,dyspnea,hoarseness and barking cough in two group all had significant differences(all P<0.05).The adverse drug reactions in control group were stomach discomfort and mild fever,which in treatment group were poor appetite,choking cough and increased nasal secretion.There was no difference of the incidence of adverse drug reaction between control group(11.11%)and treatment group(13.89%)(P>0.05).Conclusion Inhalation of budesonide combined with dexamethasone is beneficial to shorten the remission time of clinical symptoms,reduce inflammatory mediators,and improve the treatment effect.

关 键 词：布地奈德 地塞米松 雾化吸入 急性感染性咽喉炎 

分 类 号：R97[医药卫生—药品]